Antipsychotic Drugs Are Medco's New Personalized Medicine Target
Executive Summary
Medco will launch a research project in November that aims to validate a biomarker that may improve the cost effectiveness of atypical antipsychotics. The pharmacy benefit manager announced a research collaboration with development-stage genetic test developer SureGene on Aug. 24
You may also be interested in...
More Patient Registries Needed To Facilitate CER, Medco Exec Says
Comparative effectiveness research could benefit from broader use of registries of patients using particular drugs, Medco Research Institute President Felix Frueh said.
More Patient Registries Needed To Facilitate CER, Medco Exec Says
Comparative effectiveness research could benefit from broader use of registries of patients using particular drugs, Medco Research Institute President Felix Frueh said.
Pooled Antipsychotic Data Will Be Mined For Early Response Signals
A consortium of international drug companies hopes to leverage their pooled schizophrenia data into a means of determining which patient subgroups are most likely to respond to treatment during clinical trials.